Mereo and its development partner Ultragenyx Pharmaceutical Inc. issued a press release on July 9, 2025, "announcing that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]" Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur "around the end of the year."
Following this news, Mereo's American Depositary Receipt ("ADR") price fell over 42% on July 10, 2025.
To receive more information, please fill out the form.
